Vaginal candidiasis in women
Pro Research Analysisby 
Searched over 200M research papers
Epidemiology and Prevalence of Vaginal Candidiasis in Women
Vaginal candidiasis, also known as vulvovaginal candidiasis (VVC), is a common infection caused primarily by Candida albicans, though other Candida species like Candida glabrata are increasingly recognized as causes Moncayo2024Gonçalves2016Willems2020. It is estimated that about 75% of women will experience at least one episode of VVC in their lifetime, with some experiencing recurrent infections Moncayo2024Willems2020Valentine2025. The infection is most prevalent among women in their reproductive years, particularly those aged 15-34, but can also affect postmenopausal women, especially those with certain risk factors Moncayo2024Becker2023Gomes2024.
Risk Factors and Predisposing Conditions for Vaginal Candidiasis
Several host-related and behavioral factors increase the risk of developing vaginal candidiasis. Key risk factors include high estrogen levels (such as during pregnancy or hormone replacement therapy), uncontrolled diabetes, immunosuppression, antibiotic or corticosteroid use, and genetic predispositions Moncayo2024Gonçalves2016Willems2020+2 MORE. Behavioral factors such as poor menstrual hygiene, use of non-cotton or unclean undergarments, unsafe sexual practices, and use of oral contraceptives or intrauterine devices also contribute to the risk Gonçalves2016Gomes2024. In postmenopausal women, the risk is generally lower due to decreased estrogen and glycogen levels, but medications like tamoxifen, antibiotics, and certain diabetes drugs can increase susceptibility .
Symptoms and Clinical Presentation of Vaginal Candidiasis
The most common symptoms of vaginal candidiasis include itching, irritation, swelling near the genital area, abnormal white vaginal discharge, pain or burning during urination, and painful intercourse Moncayo2024Willems2020Gomes2024. These symptoms are caused by an inflammatory response triggered by the overgrowth of Candida in the vaginal environment Willems2020Valentine2025.
Pathogenesis: Host-Pathogen-Microbiome Interactions
Candida albicans is normally a harmless commensal organism in the vaginal microbiota, but under certain conditions, it can transition to a pathogenic state. This transition involves changes in fungal morphology and the expression of virulence factors such as biofilm formation and phenotypic switching, which help the fungus invade tissues and resist treatment Valentine2025Mallick2025Czechowicz2022. The vaginal microbiome, particularly the dominance of Lactobacillus species, plays a protective role by antagonizing Candida overgrowth .
The host immune response is complex. Unlike other mucosal infections, VVC is not typically associated with defective T-cell immunity. Instead, symptomatic infections are linked to an aggressive response by polymorphonuclear neutrophils, while protection appears to be mediated by non-inflammatory innate immunity Fidel2005Czechowicz2022. This unique immune response contributes to the recurrence and persistence of symptoms in some women Valentine2025Fidel2005.
Diagnosis and Treatment of Vaginal Candidiasis
Diagnosis is usually confirmed by laboratory tests or cultures to identify Candida species . Treatment typically involves antifungal medications, with azole antifungals like fluconazole being the most common. Both oral and topical antifungals are effective for uncomplicated cases, while complicated or recurrent cases may require longer or repeated courses of therapy Moncayo2024Willems2020Becker2023. Avoiding excess moisture and improving hygiene can help prevent recurrences Moncayo2024Gomes2024.
Antifungal Resistance and Recurrent Infections
Antifungal resistance is an emerging problem, especially in recurrent cases. Resistance can develop through genetic mutations, overexpression of drug efflux pumps, and increased biofilm formation, making infections harder to treat . Hormonal fluctuations, immune changes, and disruptions in the vaginal microbiome can also contribute to treatment failures and recurrences Willems2020Mallick2025.
Future Directions: Vaccines and Novel Therapies
Research is ongoing to develop vaccines and new therapies for recurrent VVC. Promising results have been seen with vaccines targeting Candida virulence factors, such as the PEV7 vaccine, which has shown potential in both animal models and early clinical trials . Understanding the complex interactions between Candida, the host immune system, and the vaginal microbiome is key to developing more effective prevention and treatment strategies Valentine2025De Bernardis2018Czechowicz2022.
Conclusion
Vaginal candidiasis is a widespread and often recurrent infection that significantly impacts women's health and quality of life. Awareness of risk factors, early diagnosis, and appropriate treatment are essential. Ongoing research into antifungal resistance, host-pathogen interactions, and novel therapies holds promise for better management and prevention of this common condition.
Sources and full results
Most relevant research papers on this topic